177 related articles for article (PubMed ID: 34851477)
21. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.
Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Bergh A; Ljungberg B
Eur Urol; 2006 Dec; 50(6):1272-7. PubMed ID: 16814458
[TBL] [Abstract][Full Text] [Related]
22. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
[TBL] [Abstract][Full Text] [Related]
23. CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1α (HIF-1α).
Sun C; Song H; Zhang H; Hou C; Zhai T; Huang L; Zhang L
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1619-24. PubMed ID: 22614155
[TBL] [Abstract][Full Text] [Related]
24. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
25. Single and joint oxidative stress-related toxicity of sediment-associated cadmium and lead on Bellamya aeruginosa.
Liu X; Chen Q; Ali N; Zhang J; Wang M; Wang Z
Environ Sci Pollut Res Int; 2019 Aug; 26(24):24695-24706. PubMed ID: 31240645
[TBL] [Abstract][Full Text] [Related]
26. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
[TBL] [Abstract][Full Text] [Related]
27. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
28. Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?
Ng KL; Del Vecchio SJ; Samaratunga H; Morais C; Rajandram R; Vesey DA; Wood ST; Gobe GC
Pathology; 2018 Aug; 50(5):504-510. PubMed ID: 29970253
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
[TBL] [Abstract][Full Text] [Related]
30. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
[TBL] [Abstract][Full Text] [Related]
31. Molecular and Genomic Profiling to Identify Actionable Targets in Chromophobe Renal Cell Cancer.
Abbosh P; Sundararajan S; Millis SZ; Hauben A; Reddy S; Geynisman DM; Uzzo R
Eur Urol Focus; 2018 Dec; 4(6):969-971. PubMed ID: 28753842
[TBL] [Abstract][Full Text] [Related]
32. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
[TBL] [Abstract][Full Text] [Related]
33. [Expression of BNIP3 and its correlations to HIF-1alpha and VEGF in clear cell renal cell carcinoma].
Luo L; Xiong ZB; Zeng H; Chen N; Chen XQ; Zhang P; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):79-82. PubMed ID: 22455137
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma.
Tsuchiya N; Sato K; Akao T; Kakinuma H; Sasaki R; Shimoda N; Satoh S; Habuchi T; Ogawa O; Kato T
Tohoku J Exp Med; 2001 Oct; 195(2):101-13. PubMed ID: 11846206
[TBL] [Abstract][Full Text] [Related]
35. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxicity evaluation and antioxidant enzyme expression related to heavy metals found in tuna by-products meal: An in vitro study in human and rat liver cell lines.
Saïdi SA; Azaza MS; Windmolders P; van Pelt J; El-Feki A
Exp Toxicol Pathol; 2013 Nov; 65(7-8):1025-33. PubMed ID: 23578882
[TBL] [Abstract][Full Text] [Related]
37. Tissue expression and plasma levels of adrenomedullin in renal cancer patients.
Michelsen J; Thiesson H; Walter S; Ottosen PD; Skøtt O; Jensen BL
Clin Sci (Lond); 2006 Jul; 111(1):61-70. PubMed ID: 16515534
[TBL] [Abstract][Full Text] [Related]
38. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
[TBL] [Abstract][Full Text] [Related]
39. Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha.
Lidgren A; Bergh A; Grankvist K; Rasmuson T; Ljungberg B
BJU Int; 2008 Feb; 101(4):480-4. PubMed ID: 17922867
[TBL] [Abstract][Full Text] [Related]
40. Chromophobe renal cell carcinoma: New genetic and metabolic insights.
Zhang L; Henske EP
Urol Oncol; 2020 Aug; 38(8):678-681. PubMed ID: 32444178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
